Xarelto Lawsuit Plaintiffs Now Number Over 3,300 Within Just Five Year’s Time

March 09, 2016 – – BloodThinnerHelp.com reports on an overview of the now more than 3,300 Xarelto lawsuits which have been filed since 2011 alone. The U.S. Food and Drug Administration approved the new-generation, blood-thinning drug in 2011 to treat patients recovering from hip and knee replacement surgeries, suffering from deep vein thrombosis and pulmonary embolism, or atrial fibrillation. The drug was long-awaited and launched onto the market as a revolutionary new anticoagulant which provided those requiring the use of blood thinners with new freedoms that traditional blood thinners hadn’t offered.

Since that time, however, more than 3,300 Xarelto lawsuits have been filed by plaintiffs from across the nation, alleging that the drug poses significant risks to users; most notably sudden bleeding episodes. The lawsuits filed have been consolidated into two major groups. In the Eastern District of Louisiana, the U.S. Judicial Panel on Multidistrict Consolidation transferred federally-filed Xarelto cases to one court. Here they have become MDL No. 2592, and are being overseen by the Honorable Judge Eldon Fallon. These cases number over 2,800 at this time, and are joined by more than 600 others which were consolidated in Philadelphia, Pennsylvania to form a mass tort group by the Court of Common Pleas.

Xarelto lawsuits in MDL 2592 are scheduled for bellwether trials, which are said to take place near the beginning of 2017. At this time, bellwether trial dates have been set for February 6, April 24, and May 30 of 2017. Plaintiffs involved in all of the Xarelto lawsuits share strikingly similar allegations and have filed their complaints against the same defendants: Xarelto manufacturers Bayer AG and Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson).

Recently, Xarelto has been the subject of even more controversy, however, as the European Regulators announced that they would be conducting an investigation into faulty testing equipment used during clinical trials on the drug, which may have led to its premature FDA approval. In addition, many are currently questioning whether manufacturers left out important information during the FDA approval process; some allege that this information was purposefully excluded.

As Xarelto lawsuit numbers continue to grow and additional investigations are done regarding the drug, Attorney Joseph Osborne is working to help ensure that anyone who feels they may have been harmed by the drug will also be given the important opportunity of exploring their legal rights in full. These individuals and their families may be entitled to legal action and substantial compensation. To better assist those wishing to pursue justice, Attorney Osborne is offering free legal consultations at this time for affected parties.

To ask questions or request additional Xarelto lawsuit information, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008594